BB Biotech

Daniel Koller: Three decades of biotech evolution

US still offering the most biotech names

08 January 2024 • 4 min read

Underestimated newcomers: mid-cap biotech companies

Strong funding profiles

12 April 2022 • 3 min read

Biotech sell-off continues as investors turn to safer assets amid rising inflation - reports

Out of favour

10 February 2022 • 2 min read

BB Biotech's Dallas Webb: 'The fundamentals of biotech have never been stronger'

Biotechnology Q&A

24 January 2022 • 4 min read

Biotech and healthcare investors hope for rebound following weak 2021

Targeting long-term structural changes

21 January 2022 • 5 min read

Covid catalyses investment in biotech with 2022 set to be 'breakout' year

Tremendous potential, particularly in the spatial biology sector

21 January 2022 • 4 min read

Gaining exposure to biotech in times of uncertainty

Omicron variant saw wild price jumps

13 December 2021 • 4 min read

Going for the golden mean: Now is an exciting time to have a diverse biotech portfolio

Healthcare innovations worth taking a shot at

09 April 2021 • 3 min read

BB Biotech holds steady in the second quarter

INDUSTRY VOICE: Major headwinds caused by various factors weighed on investor sentiment in the healthcare sector during the second quarter. BB Biotech was not completely immune to these developments and delivered a return of 1.2% in EUR.

30 July 2018 • 2 min read

Technology

Biotech in the fight against cancer

INDUSTRY VOICE: Big players in the healthcare sector are desperate to differentiate their approved 'checkpoint inhibitors' (a drug that unleashes an immune system attack on cancer cells) by combining their use with conventional chemotherapy or other new...

22 June 2018 • 3 min read